Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

被引：0
|
作者：
Bartlett, Nancy L. [1 ]
Sehn, Laurie H. [2 ,3 ]
Matasar, Matthew [4 ]
Schuster, Stephen J. [5 ]
Assouline, Sarit [6 ]
Giri, Pratyush [7 ]
Kuruvilla, John [8 ]
Canales, Miguel [9 ]
Dietrich, Sascha [10 ]
Fay, Keith [11 ,12 ]
Ku, Matthew [13 ]
Nastoupil, Loretta [14 ]
Wei, Michael C. [15 ]
Yin, Shen [15 ]
To, Iris [15 ]
Huang, Huang [16 ]
Min, Juliana [17 ]
Bolen, Christopher R. [15 ]
Penuel, Elicia [15 ]
Budde, L. Elizabeth [18 ]
机构：
[1] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA
[2] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada
[3] Univ British Columbia, Vancouver, BC, Canada
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA
[6] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
[7] Royal Adelaide Hosp, Adelaide, SA, Australia
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] Hosp Univ La Paz, Madrid, Spain
[10] Heidelberg Univ, Heidelberg, Germany
[11] St Vincents Hosp, Sydney, NSW, Australia
[12] Royal North Shore Hosp, Sydney, NSW, Australia
[13] Univ Melbourne, St Vincents Hosp, Melbourne, Australia
[14] MD Anderson Canc Ctr, Houston, TX USA
[15] Genentech Inc, San Francisco, CA USA
[16] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[17] Roche Prod Ltd, Welwyn Garden City, Herts, England
[18] City Hope Natl Med Ctr, Duarte, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
IBCL; mosunetuzumab; bispecific antibody; relapsed/refractory; follicular lymphoma; Phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-458
引用
收藏
页码：S453 / S453
页数：1
相关论文
共 50 条
  • [21] Updated Results From a Rapcabtagene Autoleucel (YTB323) Phase I Study Demonstrate Durable Efficacy and a Manageable Safety Profile in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Shah, Nirav N.
    Flinn, Ian
    Kwon, Mi
    Jaeger, Ulrich
    Briones, Javier
    Bachy, Emmanuel
    Blaise, Didier
    Boissel, Nicolas
    Kato, Koji
    Riedell, Peter A.
    Frigault, Matthew J.
    Shune, Leyla O.
    Teshima, Takanori
    Ciceri, Fabio
    Fleming, Shaun A.
    Ferrari, Silvia
    Pearson, David
    Whalen, Jeanne
    Zia, Aiesha
    Davis, Jaclyn
    Masood, Aisha
    Dickinson, Michael
    Barba, Pere
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S532 - S533
  • [22] Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open Label, Registration Directed Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 11
  • [23] Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results From a Phase 2 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 6 - 7
  • [24] Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study
    Wang, Michael
    Rule, Simon
    Zinzani, Pier Luigi
    Goy, Andre H.
    Casasnovas, Rene-Olivier
    Smith, Stephen D.
    Damaj, Gandhi Laurent
    Doorduijn, Jeanette K.
    Lamy, Thierry
    Morschhauser, Franck
    Panizo, Carlos
    Shah, Bijal
    Davies, Andrew
    Eek, Richard
    Dupuis, Jehan
    Jacobsen, Eric
    Kater, Arnon P.
    Le Gouill, Steven
    Oberic, Lucie
    Robak, Tadeusz
    Jain, Preetesh
    Brock, Graham
    Patel, Priti
    Tao, Lin
    Dlugosz-Danecka, Monika
    BLOOD, 2020, 136
  • [25] Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
    Noriko Fukuhara
    Koji Kato
    Hideki Goto
    Tajima Takeshi
    Mayu Kawaguchi
    Kota Tokushige
    Koichi Akashi
    Takanori Teshima
    Hideo Harigae
    Stephen J. Schuster
    Catherine Thieblemont
    Martin Dreyling
    Nathan Fowler
    International Journal of Hematology, 2023, 117 : 251 - 259
  • [26] Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial
    Fukuhara, Noriko
    Kato, Koji
    Goto, Hideki
    Takeshi, Tajima
    Kawaguchi, Mayu
    Tokushige, Kota
    Akashi, Koichi
    Teshima, Takanori
    Harigae, Hideo
    Schuster, Stephen J.
    Thieblemont, Catherine
    Dreyling, Martin
    Fowler, Nathan
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (02) : 251 - 259
  • [27] Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial
    Matasar, Matthew
    Bartlett, Nancy L.
    Shadman, Mazyar
    Budde, Lihua E.
    Flinn, Ian
    Gregory, Gareth P.
    Kim, Won Seog
    Hess, Georg
    El-Sharkawi, Dima
    Diefenbach, Catherine S.
    Huang, Huang
    To, Iris
    Parreira, Joana
    Wu, Mei
    Kwan, Antonia
    Assouline, Sarit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : 240 - 253
  • [28] Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
    Budde, Elizabeth L.
    Bartlett, Nancy L.
    Giri, Pratyush
    Schuster, Stephen J.
    Assouline, Sarit
    Yoon, Sung-Soo
    Fay, Keith
    Matasar, Matthew J.
    Gutierrez, Norma C.
    Marlton, Paula
    Dreyling, Martin
    Yoon, Dok Hyun
    Hess, Georg
    Radford, John
    Wiebking, Volker
    Yin, Shen
    Cybulski, Eva
    Turner, David C.
    Huang, Huang
    Zhou, Mingzhu
    Penuel, Elicia
    Wei, Michael C.
    Sehn, Laurie H.
    BLOOD, 2022, 140 : 3753 - 3755
  • [29] Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with Relapsed/Refractory (R/R) B-cell non-Hodgkin Lymphomas (B-NHL): updated results from a Phase I/II study
    von Tresckow, B.
    Budde, L. E.
    Bartlett, N. L.
    Giri, P.
    Schuster, S. J.
    Assouline, S.
    Yoon, S. S.
    Fay, K.
    Matasar, M.
    Gutierrez, N. C.
    Marlton, P.
    Dreyling, M.
    Yoon, D. H.
    Hess, G.
    Radford, J.
    Wiebking, V.
    Yin, S.
    Cybulski, E.
    Turner, D. C.
    Huang, H.
    Zhou, M.
    Penuel, E.
    Wei, M. C.
    Sehn, L. H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 206 - 207
  • [30] Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.
    Fowler, Nathan Hale
    Samaniego, Felipe
    Jurczak, Wojciech
    Lech-Maranda, Ewa
    Ghosh, Nilanjan
    Patten, Piers
    Reeves, James Andrew
    Leslie, Lori Ann
    Chavez, Julio C.
    Ghia, Paolo
    Tarella, Corrado
    Burke, John M.
    Sharman, Jeff Porter
    Kolibaba, Kathryn
    O'Connor, Owen A.
    Cheah, Chan
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345